Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C

Journal of Clinical Investigation

Volumn 99, Issue 11, 1997, Pages 2655-2663

  Petäjä, Jari ^a   Fernández, José A ^a   Gruber, András ^a   Griffin, John H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulants; Antithrombin III; Factor V; Factor Va; Protein C

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; HEPARIN; HEPARIN COFACTOR II; PROTEIN S;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; DRUG POTENTIATION; PARTIAL THROMBOPLASTIN TIME; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0345176222     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119454     Document Type: Article

References (62)

1. Baruch, D., T. Lindhout, R. Wagenwoord, and H.C. Hemker. 1986. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III. Haemostasis. 16: 71-81.
2. Hirsh, J., R. Raschke, T. Wakentin, J.E. Dalen, D. Deykin, and L. Poller. 1995. Heparin. Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 108:258s-275s.
3. Sobel, M., P.M. McNeill, P.L. Carlson, J.C. Kermode, B. Adelman, R. Conroy, and D. Marques. 1991. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J. Clin. Invest. 87:1787-1793.
4. Barrow, R.T., E.T. Parker, S. Krishnaswamy, and P. Lollar. 1994. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J. Biol. Chem. 269:26796-26800.
5. Barrow, R.T., J.F. Healey, and P. Lollar. 1994. Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex. J. Biol. Chem. 269:593-598.
6. Griffin, J.H., B. Evatt, T.S. Zimmerman, A.J. Kleiss, and C. Wideman. 1981. Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest. 68:1370-1373.
7. Branson, H.E., I. Katz, R. Marble, and J.H. Griffin. 1983. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. ii:1165-1168.
8. Dahlbäck, B. 1995. The protein C anticoagulant system: Inherited defects as basis for venous thrombosis. Thromb. Res. 77:1-43.
9. Dahlbäck, B., M. Carlsson, and P.J. Svensson. 1993. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA. 90:1004-1008.
10. Griffin, J.H., B.L. Evatt, C. Wideman, and J.A. Fernández. 1993. Anticoagulant protein C pathway is defective in a majority of thrombophilic patients. Blood. 82:1989-1993.
11. Koster, T., F.R. Rosendaal, H. de Ronde, E. Briët, J.P. Vandenbroucke, and R.M. Bertina. 1993. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden thrombophilia study. Lancet. 342:1503-1506.
12. Svensson, P.J., and B. Dahlbäck. 1994. Resistance to activated protein C as a basis for venous thrombosis. N. Engl. J. Med. 330:517-522.
13. Bertina, R.M., B.P.C. Koeleman, T. Koster, F.R. Rosendaal, R.J. Dirven, H. de Ronde, P.A. Velden, and P.H. Reitsma. 1994. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (Lond.). 369:64-67.
14. Greengard, J.S., X. Sun, X. Xu, J.A. Fernández, J.H. Griffin, and B. Evatt. 1994. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 343:1361-1362.
15. 506 of factor V. Lancet. 343: 1535-1536.
16. Sun, X., B. Evatt, and J.H. Griffin. 1994. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood. 83:3120-3125.
17. Dreyfus, M., J.F. Magny, F. Bridey, H.P. Schwarz, C. Planché, M. Dehan, and G. Tchernia. 1991. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N. Engl. J. Med. 325:1565-1568.
18. Schramm, W., M., Spannagl, K.A. Bauer, R.D. Rosenberg, B. Birkner, Y. Linnau, and H.P. Schwarz. 1993. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch. Dermatol. 129:753-756.
19. Marlar, R. A., and J.H. Griffin. 1980. Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J. Clin. Invest. 66:1186-1189.
20. Suzuki, K., Nishioka J., Kusumoto H., and S. Hashimoto. 1984. Mechanism of inhibition of activated protein C by protein C inhibitor. J. Biochem. 95: 187-195.
21. España, F., M. Berrettini, and J.H. Griffin. 1989. Purification and characterization of plasma protein C inhibitor. Thromb. Res. 55:369-384.
22. Hirahara, K., Y. Etoh, T. Matsuishi, N. Suzuki, and M. Kurata. 1989. Synergistic effect of antithrombin III, activated protein C and heparin on the inhibition of the tissue thromboplastin-mediated coagulation. Chem. Pharm. Bull. 37:692-696.
23. Hackeng, T.M., C. van't Veer, J.C.M. Meijers, and B.N. Bouma. 1994. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J. Biol. Chem. 269: 21051-21058.
24. Gruber, A., L.A. Harker, S.R. Hanson, A.B. Kelly, and J.H. Griffin. 1991. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation. 84:2454-2462.
25. Heeb, M.J., Y. Kojima, J.S. Greengard, and J.H. Griffin. 1995. Activated protein C resistance. Molecular mechanisms based on studies using purified Gln506-factor V. Blood. 85:3405-3411.
26. Nesheim, M.E., W.M. Canfield, W. Kisiel, and K.G. Mann. 1982. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J. Biol. Chem. 257:1443-1447.
27. Solymoss, S., M.M. Tucker, and P.B. Tracy. 1988. Kinetics of inaclivation of membrane-bound factor Va by activated protein C. J. Biol. Chem. 263: 14884-14890.
28. van Putten, J.J., M. van de Ruit, M. Beunis, and H.C. Hemker. 1982. Interindividual variation in relationships between plasma heparin concentration and the results of five heparin assays. Clin. Chim. Acta. 122:261-270.
29. Hanson, S.R., J.H. Griffin, L.A. Harker, A.B. Kelly, C.T. Esmon, and A. Gruber. 1993. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J. Clin. Invest. 92:2003-2012.
30. Gruber, A., and J.H. Griffin. 1992. Direct detection of activated protein C in blood from human subjects. Blood. 79:2340-2348.
31. Gruber, A., A. Pal, R.G. Kiss, G. Sas, and J.H. Griffin. 1993. Generation of activated protein C during thrombolysis. Lancet. 342:1275-1276.
32. Walker, F.J. 1980. Regulation of activated protein C by a new protein. J. Biol. Chem. 255:5521-5524.
33. Esmon, C.T. 1992. The protein C anticoagulant pathway. Arterioscler. Thromb. 12:135-145.
34. Fulcher, C.A., J.E. Gardiner, J.H. Griffin, and T.S. Zimmerman. 1984. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood. 63:486-489.
35. Marlar, R.A., A.J. Kleiss, and J.H. Griffin. 1982. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 59:1067-1072.
36. Fay, P.J., T.M. Smudzin, and F.J. Walker. 1991. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J. Biol. Chem. 266:20139-20145.
37. Regan, L.M., L.M. O'Brien, T.L. Beattie, K. Sudhakar, F.J. Walker, and P.J. Fay. 1996. Activated protein C-catalyzed proteolysis of factor FVIIIa alters its interactions within factor Xase. J. Biol. Chem. 271:3982-3987.
38. Ofosu, F.A., M.A. Blajchman, G. Modi, A.L. Cerskus, and J. Hirsh. 1981. Activation of factor X and prothrombin in antithrombin III depleted plasma. The effects of heparin. Thromb. Res. 23:331-345.
39. Schoen, P., and T. Lindhout. 1991. Flow and the inhibition of prothrombinase by antithrombin III and heparin. Blood. 78:118-124.
40. Ofosu, F.A., J.C. Lormeau, S. Craven, L. Dewar, and N. Anvari. 1994. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma. Thromb. Haemostasis. 72:862-868.
41. Ofosu, F.A., P. Sie, G.J. Modi, F. Fernandez, M.R. Buchanan, M.A. Blajchman, B. Boneu, and J. Hirsh. 1987. The inhibition of thrombin-dependent feedback reactions is critical to the expression of anticoagulant effects of heparin. Biochem. J. 243:579-588.
42. Ofosu, F.A. 1989. Antithrombotic mechanisms of heparin and related compounds. In Heparin. Chemical and Biological Properties, Clinical Applications. D.A. Lane, and U. Lindahl, editors. CRC Press Inc., Boca Raton, FL.
43. Pieters, J., and T. Lindhout. 1988. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood. 72:2048-2052.
44. Buchanan, M.R., B. Boneu, F. Ofosu, and J. Hirsh. 1985. The relative importance of thrombin inhibition and factor Xa inhibition to antithrombotic effects of heparin. Blood. 65:198-201.
45. Monkovic, D.D., and P.B. Tracy. 1990. Activation of human factor V by factor Xa and thrombin. Biochemistry. 29:1118-1128.
46. Foster, W.B., M.E. Nesheim, and K.G. Mann. 1983. The factor Xa-catalyzed activation of factor V.J. Biol. Chem. 258:13970-13977.
47. Ofosu, F.A., J. Hirsh. C.T. Esmon, G.J. Modi, L.M. Smith, N. Anvari, M.R. Buchanan, J.W. Fenton, and M.A. Blajchman. 1989. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem. J. 257:143-150.
48. Suzuki, K., J. Stenflo, B. Dahlbäck, and B. Teodorsson. 1983. Inactivation of human coagulation factor V by activated protein C. J. Biol. Chem 258: 1914-1920.
49. Kalafatis, M., M.D. Rand, and K.G. Mann. 1994. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J. Biol. Chem. 269:31869-31880.
50. Krishnaswamy, S., E.B. Williams, and K.G. Mann. 1986. The binding of activated protein C to factors V and Va. J. Biol. Chem. 261:9684-9693.
51. Deshun, L., M. Kalafatis, K.G. Mann, and G.L. Long. 1996. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood. 87:4708-4717.
52. Kalafatis, M., P.E. Haley, D. Lu, R.M. Bertina, G.L. Long, and K.G. Mann. 1996. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting. An insight into the APC-resistance assay. Blood. 87:4695-4707.
53. R506Q. J. biol. Chem. 270:4053-4057.
54. Keller, F.G., T.L. Ortel, M.A. Quinn-Allen, and W.H. Kane. 1995. Thrombin-catalyzed activation of human factor V. Biochemistry. 34:4118-4124.
55. 2Cl. Biochem. J. 272:399-406.
56. Beguin, S., T. Lindhout, and H.C. Hemker. 1988. The mode of action of heparin in plasma. Thromb. Haemostasis. 60:451-462.
57. Higgins, D.L., and K.G. Mann. 1983. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J. Biol. Chem. 258: 6503-6506.
58. Sakamoto, T., H. Ogawa, H. Yasue, Y. Oda, S. Kitajima, K. Tsumoto, and H. Mizokami. 1994. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis. Circulation. 90:427-432.
59. Kazama, Y., and T. Koide. 1992. Modulation of protein C inhibitor activity by histidine-rich glycoprotein and platelet factor 4. Role of zinc and calcium ions in the heparin-neutralizing ability of histidine-rich glycoprotein. Thromb. Haemostasis. 67:50-55.
60. Dollery, C., I. Sullivan, O. Bauraind, C. Bull, and P.J. Milla. 1994. Thrombosis and embolism in long-term central venous access for parenteral nutrition. Lancet. 344:1043-1045.
61. Woodman, R.C., and L.A. Harker. 1990. Bleeding complications associated with cardiopulmonary bypass. Blood. 76:1680-1697.
62. Petäjä, J., K. Peltola, H. Sairanen, M. Leijala, R. Kekomäki, E. Vahtera, and M.A. Siimes. 1996. Fibrinolysis, antithrombin III and protein C in neonates during open heart surgery. J. Thoracic Cardiovasc. Surg. 112:665-671.